A new poll has found that most Americans support gene editing that is used to protect babies against diseases; Maine’s incoming governor, a Democrat, may be able to ignore the Medicaid work requirements the federal government just approved for the outgoing Republican governor; the new trade agreement between the United States, Canada, and Mexico includes language that could delay cheaper generics from reaching patients.
A new poll has found that most Americans support gene editing that is used to protect babies against diseases. However, they don’t believe the technology should be used to make children smarter, faster, or taller, according to the Associated Press. Approximately 70% of Americans are in favor of using gene editing to prevent fatal or uncurable diseases and two-thirds find it acceptable to also use gene editing to protect against nonfatal conditions and reduce the risk of diseases developing later in life. The poll also found more Americans believe the government should not fund testing on human embryos to develop gene-editing technology.
Maine’s outgoing governor, Republican Paul LePage, was strongly opposed to Medicaid expansion, and after his state’s voters approved expansion at the polls, he got approval from the federal government to implement work requirements. According to the Portland Press Herald, the incoming governor, a Democrat, may be able to ignore those work requirements when she takes office. An expert suggested that just because the waiver was approved by the government, doesn’t mean Governor-elect Janet Mills has to follow it. Mills is currently evaluating the legal options available to her.
The new trade agreement between the United States, Canada, and Mexico included language that prevents generic copies of Canada and Mexico’s prescription drugs from reaching the market for at least a decade. The United States grants 12 years of market protection, while Canada grants 8 years and Mexico only 5 years. USA Today reported that some fear this agreement could delay efforts to get cheaper generics to patients. Congress still has to approve the trade agreement and House Democrats, who take the majority in January, are expected to demand changes to the drug provision and other parts of the trade deal.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More